Coenzyme A fuels T cell anti-tumor immunity

Area of Science:

• Immunology
• Metabolism
• Cancer Research

Background:

• Metabolic programming critically influences T cell anti-tumor functions.
• Understanding metabolic pathways driving T cell activity is key for improving cancer immunotherapies.

Purpose of the Study:

• To investigate metabolic pathways linked to enhanced CD8+ T cell anti-tumor activity.
• To identify key metabolites that can reprogram T cells for improved anti-tumor immunity.

Main Methods:

• Utilized metabolomics to analyze three CD8+ T cell subsets with distinct anti-tumor functions in murine models.
• Investigated the role of pantothenate and coenzyme A (CoA) in T cell differentiation and function.
• Assessed the impact of exogenous CoA and pantothenate administration on T cell metabolism and anti-tumor efficacy in vivo.
• Correlated plasma pantothenic acid levels with anti-PD1 therapy response in melanoma patients.

Main Results:

• IL-22-producing Tc22 cells exhibited the strongest anti-tumor activity and upregulated the pantothenate/CoA pathway.
• Tc22 differentiation required oxidative phosphorylation (OXPHOS).
• Exogenous CoA administration promoted OXPHOS and the Tc22 phenotype via HIF-1α and AhR.
• Pantothenate treatment enhanced anti-PDL1 therapy efficacy in murine tumor models.
• Higher plasma pantothenic acid levels correlated with better response to anti-PD1 therapy in melanoma patients.

Conclusions:

• Pantothenate and CoA are crucial drivers of T cell polarization, bioenergetics, and anti-tumor immunity.
• Targeting the pantothenate-CoA pathway represents a promising strategy to enhance cancer immunotherapy.